Viron Therapeutics is a clinical stage biopharmaceutical company pioneering the development of viral proteins to treat and prevent human inflammatory disorders. Viral proteins represent a revolutionary new class of drugs. By harnessing the evolutionary power of viruses and other pathogens to evade the human body's protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy. Viron is the first company to successfully advance a viral protein drug into human testing.
Funding Rounds (1) - $20MUpdate
Board Members and Advisors (1)Update
|May 21, 2015||Business Wire - Research and Markets: Restenosis Pipeline Review 2015 - 7 Companies & 14 Drug Profiles|
|Apr 1, 2015||PRNewswire UK All - Restenosis Therapeutic Pipeline and Development Review H1 2015 Market Research Report|
|Apr 21, 2010||vironinc.com - Viron Therapeutics raises 20000000 in venture round|
700 Collip Circle, Suite 203
London, N6G 4X8